Kura Oncology Inc. (NASDAQ:KURA) has been given an average broker rating score of 1.00 (Strong Buy) from the two analysts that provide coverage for the stock, Zacks Investment Research reports. Two research analysts have rated the stock with a strong buy rating.
Brokers have set a 1-year consensus price target of $20.00 for the company and are predicting that the company will post ($0.41) EPS for the current quarter, according to Zacks. Zacks has also assigned Kura Oncology an industry rank of 111 out of 265 based on the ratings given to its competitors.
KURA has been the topic of a number of recent analyst reports. Zacks Investment Research upgraded Kura Oncology from a “hold” rating to a “buy” rating and set a $3.75 target price on the stock in a report on Wednesday, July 13th. Oppenheimer Holdings Inc. reiterated an “outperform” rating and set a $16.00 price objective on shares of Kura Oncology in a report on Tuesday, June 21st. Finally, Leerink Swann reiterated an “outperform” rating and set a $15.00 price objective on shares of Kura Oncology in a report on Thursday.
Shares of Kura Oncology (NASDAQ:KURA) traded down 5.90% during midday trading on Friday, reaching $5.42. The company’s stock had a trading volume of 26,693 shares. Kura Oncology has a 12 month low of $2.50 and a 12 month high of $25.00. The company has a 50-day moving average price of $6.15 and a 200-day moving average price of $4.19. The firm’s market cap is $101.59 million.
Kura Oncology (NASDAQ:KURA) last issued its earnings results on Wednesday, August 10th. The company reported ($0.36) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.34) by $0.02. Equities analysts expect that Kura Oncology will post ($1.58) earnings per share for the current year.
An institutional investor recently bought a new position in Kura Oncology stock. Alethea Capital Management LLC bought a new stake in shares of Kura Oncology Inc. (NASDAQ:KURA) during the second quarter, according to its most recent disclosure with the SEC. The institutional investor bought 62,000 shares of the company’s stock, valued at approximately $168,000. Alethea Capital Management LLC owned 0.34% of Kura Oncology as of its most recent filing with the SEC. Institutional investors and hedge funds own 43.63% of the company’s stock.
Kura Oncology Company Profile
Kura Oncology, Inc is a clinical-stage biopharmaceutical company. The Company is engaged in discovering and developing personalized therapeutics for the treatment of solid tumors and blood cancers. Its segment is engaged in the discovery and development of personalized therapeutics for the treatment of solid tumors and blood cancers.